The Cigna Group (CI) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
13 Mar, 2026Executive summary
Annual meeting scheduled for April 22, 2026, with voting available online or virtually at the meeting.
Shareholders are encouraged to review proxy materials online or request copies before voting.
Voting matters and shareholder proposals
Election of 12 directors, each recommended by the board for approval.
Advisory vote on executive compensation, with board recommending approval.
Ratification of PricewaterhouseCoopers LLP as independent auditor for 2026, recommended by the board.
Shareholder proposal on the right to act by written consent, with board recommending a vote against.
Record date for voting eligibility set as February 23, 2026.
Board of directors and corporate governance
Nominees for director include individuals with diverse backgrounds and expertise.
Board provides recommendations for each director nominee and all voting items.
Latest events from The Cigna Group
- Q2 2026 revenues rose 7% to $71.7B, adjusted EPS $7.78, and full-year EPS outlook raised to $30.45.CI
Q2 2026 - Specialty drug innovation and biosimilars drive rapid growth and cost savings in healthcare.CI
Bernstein Healthcare 1:1 Forum 2024 - Rebate-free PBM model scales by 2028; specialty and AI drive growth and efficiency.CI
Bank of America Global Healthcare Conference 2026 - Q1 2026 saw higher revenues, profits, and a raised outlook, driven by strong segment results.CI
Q1 2026 - Board and management proposals passed; shareholder written consent proposal failed.CI
AGM 2026 - Strong 2025 results, portfolio focus, and leadership transition headline this year’s proxy.CI
Proxy Filing - Q2 2025 revenue up 11% to $67.2B, adjusted EPS $7.20, and EPS guidance reaffirmed at $29.60+.CI
Q2 2025 - Q3 2024 revenue up 30% to $63.7B, EPS up 11%, net income down on VillageMD loss.CI
Q3 2024 - 2024 revenue up 27% to $247.1B; 2025 outlook strong with higher EPS and capital returns.CI
Q4 2024